DoD Multiple Sclerosis, Early Investigator Research Award
ID: 353640Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Fiscal Year 2024 Multiple Sclerosis Research Program (MSRP) Early Investigator Research Award (EIRA) to support innovative research in Multiple Sclerosis (MS). This grant opportunity is aimed at postdoctoral researchers with less than four years of experience who are committed to dedicating at least 50% of their effort to the proposed research, and requires the inclusion of a mentor with proven experience in MS research. The total funding available for FY24 is $20 million, with individual project funding capped at $320,000 over two years, and applications must address specific focus areas such as central nervous system repair and MS etiology. Interested applicants should note that the pre-application deadline is July 24, 2024, with full applications due by October 7, 2024; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Defense's Fiscal Year 2024 (FY24) Multiple Sclerosis Research Program (MSRP) is announcing its Early Investigator Research Award (EIRA) aimed at supporting innovative research in Multiple Sclerosis (MS). The total funding available for FY24 is $20 million, supporting projects relevant to active-duty service members, veterans, and the broader public. Applications must address specific focus areas, including central nervous system repair, disease activity progression, symptom biology, and MS etiology. Eligible applicants include postdoctoral researchers with less than four years of experience and who commit at least 50% of their effort to the proposed research. A mentor with proven experience in MS research is required. The application process has two steps: a pre-application due by July 24, 2024, and a full application by October 7, 2024. The maximum funding for each project is limited to $320,000 over two years. Applications will undergo peer and programmatic reviews to evaluate scientific merit and relevance to military health priorities. Clinical trials are excluded from this funding opportunity. This announcement reflects the Department's commitment to addressing significant health concerns associated with Multiple Sclerosis through research and innovation.
    Similar Opportunities
    DoD Multiple Sclerosis, Investigator-Initiated Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Materiel Command (USAMRAA), is offering a funding opportunity for the Fiscal Year 2024 Multiple Sclerosis Research Program (MSRP) via the Investigator-Initiated Research Award (IIRA). This grant aims to support innovative and high-impact research projects related to Multiple Sclerosis (MS), particularly those that can enhance patient care and quality of life, while excluding clinical trials. The program emphasizes research on central nervous system repair, disease progression correlates, symptom biology, and MS etiology, with a total funding pool of $6 million expected to yield approximately six awards, each up to $1 million over three years. Interested applicants must submit a pre-application by June 10, 2024, followed by a full application due by October 7, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Multiple Sclerosis, Exploration - Hypothesis Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is inviting applications for the FY24 Multiple Sclerosis Exploration - Hypothesis Development Award (MSRP EHDA), aimed at fostering innovative research in the field of multiple sclerosis (MS). This grant program supports high-risk, high-gain research concepts that challenge existing paradigms and lay the groundwork for future scientific investigations, with a focus on areas such as central nervous system repair and mechanisms contributing to MS etiology. The total estimated funding for this program is approximately $2 million, with an expected eight awards, and applications must follow a two-step submission process, including a pre-application due by June 10, 2024, and a full application due by October 7, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Multiple Sclerosis, Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Multiple Sclerosis Clinical Trial Award to support clinical trials aimed at improving treatment and management of multiple sclerosis (MS). This funding opportunity encourages innovative trials that may include new pharmacologic agents, devices, or emerging technologies, with a total estimated program funding of $8 million and the expectation of awarding three grants. Eligible applicants include unrestricted entities, and the funding levels are set at a maximum of $2 million for small-scale trials and $4 million for larger-scale studies, with a pre-application deadline of June 10, 2024, and a full application deadline of October 7, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    CDMRP Neurofibromatosis Early Investigator Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is offering the Neurofibromatosis Early Investigator Research Award, a federal grant aimed at supporting innovative research in neurofibromatosis (NF). This opportunity is specifically designed for early-stage investigators to develop research projects under the guidance of experienced mentors, focusing on understanding, diagnosing, and treating NF1, NF2, and schwannomatosis disorders. With a total estimated program funding of $640,000 and an expected two awards, each grant will not exceed $200,000 over a performance period of two years. Interested applicants must submit their proposals by October 3, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    CDMRP Neurofibromatosis New Investigator Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Neurofibromatosis New Investigator Award to support innovative research in neurofibromatosis (NF). This grant aims to foster the development of early-stage investigators and facilitate the transition of established researchers from other fields into NF research, with a focus on enhancing understanding, diagnosis, and treatment of NF. Eligible applicants include both early-stage and established investigators, and while prior experience in NF research is not required, collaboration with experienced researchers is encouraged. The total estimated funding for this program is $2,880,000, with up to four awards expected, each allowing for direct costs not exceeding $450,000 over a maximum of three years. Interested applicants must submit a pre-application by October 3, 2024, followed by a full application, and can reach the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Reconstructive Transplant Research, Investigator-Initiated Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is inviting applications for the FY24 Reconstructive Transplant Research Program (RTRP) Investigator-Initiated Research Award, aimed at advancing reconstructive transplant research and improving healthcare for military service members and veterans. This grant opportunity seeks proposals that focus on vascularized composite allotransplantation (VCA) and immunotherapy, emphasizing the optimization of immunosuppressive techniques, identification of noninvasive biomarkers for graft rejection monitoring, and development of tissue preservation strategies. With an estimated total program funding of $4 million, individual principal investigator applications can receive up to $1 million, while multiple principal investigator collaborations may secure up to $1.5 million, contingent upon successful peer review. The pre-application deadline is August 7, 2024, and the full application deadline is October 23, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Combat Readiness - Medical, Translational Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Combat Readiness - Medical Translational Research Award (CRRP TRA) to support high-impact translational research aimed at enhancing medical readiness for military personnel. This funding opportunity seeks proposals that address critical areas such as battlefield diagnostics, treatments for life-threatening injuries, and operational health threats, with an emphasis on projects that leverage existing resources and demonstrate clear relevance to military health. The total estimated funding for this initiative is approximately $3.3 million, with the expectation of awarding around three grants, and key deadlines include pre-applications due by September 4, 2024, and full proposals by December 5, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Arthritis Research, Clinical Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Arthritis Research Clinical Research Award (ATRP CRA) to support clinical research aimed at improving the understanding and management of various forms of arthritis, particularly in military personnel and their families. This grant program encourages innovative research proposals that address disease-specific factors and interventions, with a focus on enhancing patient outcomes and informing clinical care or policy. With an estimated total funding of $6 million, the program anticipates awarding approximately three grants, including one for a clinical trial, with applications due by October 30, 2024, and a pre-application deadline of October 16, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    CDMRP Neurofibromatosis Investigator-Initiated Research Program
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Neurofibromatosis Investigator-Initiated Research Program (NFRP) grant to support innovative research projects focused on neurofibromatosis (NF). This program aims to enhance understanding, diagnosis, and treatment of NF1, NF2, and schwannomatosis, with a particular emphasis on improving the quality of life for affected individuals, including military personnel and veterans. The total estimated funding for this initiative is $5.36 million, with up to six awards anticipated, and applications must be submitted by October 3, 2024, following a pre-application deadline of September 12, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Bone Marrow Failure, Investigator-Initiated Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Bone Marrow Failure Research Program (BMFRP) Investigator-Initiated Research Award, aimed at advancing research on bone marrow failure (BMF) diseases. This grant opportunity includes two funding levels: Funding Level 1 (FL1) focuses on developing mature ideas and translating discoveries into clinical applications, while Funding Level 2 (FL2) supports efforts to facilitate Investigational New Drug (IND) applications for promising therapeutic candidates. With a total estimated funding of $2.44 million available for two awards, the program encourages innovative and collaborative research proposals that address critical questions in BMF disease management. Interested applicants must submit a pre-application by July 17, 2024, with the full application due by October 9, 2024; for assistance, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.